The Source • April/May 2008 • Issue 101
Lessons and Questions from the E2100 Avastin Breast Cancer Trial
Share this: Facebook Twitter Email Gmail Yahoo! Mailby Robert Erwin The Food and Drug Administration (FDA) granted accelerated approval this past February to biotech company Genentech to market Avastin (bevacizumab) for the treatment of metastatic breast cancer. The FDA defines “accelerated approval” as “a provisional… Read More
Putting Patients First: The Need for Better Standards at the FDA
Share this: Facebook Twitter Email Gmail Yahoo! Mailby Barbara A. Brenner I have written frequently about the Food and Drug Administration for this column. It has never seemed more important than now to spell out in the clearest possible terms what breast cancer patients need… Read More
Healthy Job, Healthy Body A Profile of Women’s Action to Gain Economic Security
Share this: Facebook Twitter Email Gmail Yahoo! Mailby Pauli Ojea Imagine a stable job that pays well, includes benefits, provides opportunities for education and training, and is safe and healthy for workers. (If this describes your own job, you’re better off than most people in… Read More
a project of Breast Cancer Action